Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 20/20 | 0.74 |
| ▸ | WDR77 | Q9BQA1 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21356293 | 1.00 | PRMT5 (0.74) | PRMT5WDR77 | |
| SCHEMBL24489732 | 1.00 | PRMT5 (0.74) | PRMT5WDR77 | |
| SCHEMBL21356084 | 1.00 | PRMT5 (0.74) | PRMT5WDR77 | |
| SCHEMBL29383028 | 1.00 | PRMT5 (0.74) | PRMT5WDR77 | |
| SCHEMBL29384103 | 0.93 | PRMT5 (0.74) | PRMT5WDR77 | |
| SCHEMBL21355973 | 0.93 | PRMT5 (0.74) | PRMT5WDR77 | |
| SCHEMBL22517602 | 0.91 | PRMT5 (0.61) | PRMT5WDR77 | |
| SCHEMBL21356239 | 0.91 | PRMT5 (0.61) | PRMT5WDR77 | |
| SCHEMBL21355754 | 0.91 | PRMT5 (0.61) | PRMT5WDR77 | |
| SCHEMBL29383078 | 0.91 | PRMT5 (0.61) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-11-04 | — | — | US | disclosed |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-3765461-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4175718-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 2023-05-10 | — | — | EP | disclosed |
| US-20220177481-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-06-09 | — | — | US | disclosed |
| US-20220152073-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-11254683-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3946352-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | Prelude Therapeutics, Incorporated (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | PRMT5 1097/4885WDR77 4003/4885 |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | PRMT5 1426/4885WDR77 2978/4885 |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-11254683-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
| US-20220152073-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 57/4885 |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 57/4885 |
| US-20220177481-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.